Evaluation of anti-proliferative and pro-apoptotic property of 7,3′-dihydroxyflavone against MCF-7 cell line using in-vitro, in-silico and gene expression analysis

With approximately ten million deaths from cancer in 2020, cancer is a major cause of death worldwide. In 2020, around 25% of newly diagnosed cancer patients will have a breast cancer, which has the highest incidence rates. Furthermore, one-third of female cancer patients under 60 have breast cancer, and the disease accounts for 18% of cancer-related deaths.In- vitro, in- silico and gene expression studies were done to assess the 7,3′-dihydroxyflavone's anti-proliferative and pro-apoptotic activity. First, we used the MTT assay to show that 7,3′-dihydroxyflavone had anti-proliferative properties. Second, we assessed the apoptotic activity, which was verified by the Propidium Iodide Assay and Annexin V, which showed cells at every stage of the process. Third, we investigated the gene expression level of p53, p21, and Nfkb by RT-PCR analysis. Fourth, we studied the binding affinity of 7,3′-dihydroxyflavone against p53, p21, and Nfkb by cellular docking and protein-ligand interaction studies. Molecular docking of 7,3′- dihydroxyflavone were performed against p53, p21, and Nkfb receptors by using AutoDock Vina. An ADMET predictions was performed to inspect the chance of 7,3′- dihydroxyflavone being anti-cancer drug.